EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16 June 2014
gsk-location-big

UK pharma major GlaxoSmithKline (LSE: GSK) announced the results from the Phase III PETIT2 study evaluating the efficacy of eltrombopag versus placebo in pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP) at the European Haematology Association annual congress in Milan, Italy.

Eltrombopag, marketed as Promacta in the USA and as Revolade in Europe and other countries across the world, met its primary endpoint, achieving a statistically-significant improvement in platelet counts with almost 40% of patients treated with eltrombopag attaining a consistent platelet response for 6 of 8 weeks compared to placebo.

“The PETIT2 study results presented today show an increase in platelet response rate with eltrombopag treatment - an important result given that these children had failed other standard therapies,” said Rafael Amado, head of oncology R&D, GlaxoSmithKline. “We look forward to continuing to assess the potential of eltrombopag in these patients and to moving forward with planned regulatory submissions for a pediatric indication in cITP later this year.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical